Argenica Therapeutics : Change of Director's Interest Notice x2

Appendix 3Y Change of Director's Interest Notice

Appendix 3Y

Rule 3.19A.2

For personal use only

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity ARGENICA THERAPEUTICS LIMITED
ABN	38 620 388 230
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director	GEOFF POCOCK
Date of last notice	9 JUNE 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

	Direct or indirect interest	INDIRECT
	Nature of indirect interest	BENEFICIARY	OF TRUSTEE AND
	Note: Provide details of the circumstances giving rise to the relevant
	(including reg stered holder)	CONTROLLER
	interest.	2.	14 JUNE 2022
	Date of change	1	10
	No. of securities held prior to change	OOFY PROSSER PTY LTD <>
		FAMILY A/C>
		4,377,000 - FULLY PAID ORDINARY
		SHARES
		500,000 -	UNLISTED OPTIONS,
		EXERCISE PRICE $0.30, EXPIRY DATE
		30 SEP 2024
	Class	ORDINARY SHARES
		2.	27,000
	Number acquired	1	32,690
	+ See chapter 19 for defined terms.			Appendix 3Y Page 1
01/01/2011

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Number disposed	2. $11,070.00
valuation
Note: If consideration is non-cash, provide details and estimated	1	$13,532 40
Value/Considerat on	NIL
No. of securities held after change	OOFY PROSSER PTY LTD <>
	FAMILY A/C>
	4,436,690 - FULLY PAID ORDINARY
	SHARES
	500,000 - UNLISTED OPTIONS,
	EXERCISE PRICE $0.30, EXPIRY DATE
	30 SEP 2024
Example:Natureonof-marketchangetrade,off-market trade, exercise of options, issue	ON MARKET PURCHASE
of securities under dividend reinvestment plan, participation in buy-
back

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

	Detail of contract	N/A
	Nature of interest	N/A
	Name of registered holder	N/A
	(if issued securities)
	Date of change	N/A
	No. and class of securities to which	N/A
	Note: Details are only required for a contract in
	interest related prior to change
	relation to which the interest has changed	N/A
	Interest acquired
	Interest disposed	N/A
	Note:Value/ConsiderationIf consideration is non-cash, provide details	N/A
	and an estimated valuation	N/A
	Interest after change
	+ See chapter 19 for defined terms.	01/01/2011
	Appendix 3Y Page 2

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Part 3 - +Closed period

Were the interests in the securities or contracts detailed	NO
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the	N/A
trade to proceed during this period?
If prior written clearance was provided, on what date was	N/A
this provided?

+ See chapter 19 for defined terms.	Appendix 3Y Page 3
01/01/2011

Appendix 3Y Change of Director's Interest Notice

Appendix 3Y

Rule 3.19A.2

For personal use only

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity ARGENICA THERAPEUTICS LIMITED
ABN	38 620 388 230
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director	LIZ DALLIMORE
Date of last notice	9 JUNE 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

	Direct or indirect interest	INDIRECT
	Nature of indirect interest	TRUSTEE AND BENEFICIARY
	(including r g stered holder)
	Note: Provide details of the circumstances giving rise to the relevant	2.	14 JUNE 2022
	interest.
	Date of change	1	10
	No. of securities held prior to change	LEWIS	MACDONALD DAWSON &
		ELIZABETH JANE DAWSON <>
		FAMILY A/C>
		2,500,000	- UNLISTED OPTIONS,
		EXERCISE PRICE $0.30, EXPIRY DATE
		30 SEP 2024
	Class	ORDINARY SHARES
	Number acquired	2.	10,916
	1	39,084
	Number disposed	NIL
	+ See chapter 19 for defined terms.			Appendix 3Y Page 1
01/01/2011

For personal use only

Appendix 3Y

Change of Director's Interest Notice

valuation	2.	$4,366.40
Note: If consideration is non-cash, provide details and estimated	1	15,633.60
Value/Considerat on
No. of securities held after change	LEWIS	MACDONALD DAWSON &
	ELIZABETH JANE DAWSON <>
	FAMILY A/C>
	50,000 - FULLY PAID ORDINARY
	SHARES
	2,500,000	- UNLISTED OPTIONS,
	EXERCISE PRICE $0.30, EXPIRY DATE
	30 SEP 2024
Example:Natureonof-marketchangetrade,off-market trade, exercise of options, issue	ON MARKET PURCHASE
of securities under dividend reinvestment plan, participation in buy-
back

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
Note: Details are only required for a contract in
interest related prior to change
relation to which the interest has changed	N/A
Interest acquired
Interest disposed	N/A
Note:Value/ConsiderationIf consideration is non-cash, provide details	N/A
and an estimated valuation	N/A
Interest after change

+ See chapter 19 for defined terms.	01/01/2011
Appendix 3Y Page 2